Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
10.62
-0.25 (-2.30%)
At close: May 18, 2026, 4:00 PM EDT
10.60
-0.02 (-0.19%)
Pre-market: May 19, 2026, 5:44 AM EDT
Immatics Revenue
Immatics had revenue of 7.61M EUR in the quarter ending March 31, 2026, a decrease of -59.04%. This brings the company's revenue in the last twelve months to 37.30M, down -74.13% year-over-year. In the year 2025, Immatics had annual revenue of 48.27M, down -69.03%.
Revenue (ttm)
37.30M EUR
Revenue Growth
-74.13%
P/S Ratio
33.12
Revenue / Employee
52,457 EUR
Employees
711
Market Cap
1.42B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.27M | -107.57M | -69.03% |
| Dec 31, 2024 | 155.84M | 101.84M | 188.60% |
| Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
| Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
| Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
| Dec 31, 2020 | 31.25M | 12.80M | 69.40% |
| Dec 31, 2019 | 18.45M | 14.68M | 389.36% |
| Dec 31, 2018 | 3.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 596.34M |
| Immunocore Holdings | 412.81M |
| Nuvation Bio | 143.05M |
| UroGen Pharma | 140.49M |
| KalVista Pharmaceuticals | 114.48M |
| Vir Biotechnology | 65.50M |
| Monte Rosa Therapeutics | 42.95M |
| Maze Therapeutics | 20.00M |
IMTX News
- 6 days ago - Immatics reports Q1 EPS (43c), consensus (44c) - TheFly
- 7 days ago - Immatics Announces First Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 21 days ago - Immatics initiated with a Buy at TD Cowen - TheFly
- 27 days ago - Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting - GlobeNewsWire
- 4 weeks ago - Immatics abstract accepted for late-breaking poster presentation at AACR meeting - TheFly
- 2 months ago - Immatics assumed with a Buy at Jefferies - TheFly
- 2 months ago - Immatics sees cash runway into 2028 - TheFly
- 2 months ago - Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year - TheFly